Effects of endocrine disorders on lipids and lipoproteins

被引:21
作者
Newman, Connie B. [1 ,2 ]
机构
[1] New York Univ, Div Endocrinol Diabet & Metab, Grossman Sch Med, New York, NY 10016 USA
[2] 550 First Ave, New York, NY 10016 USA
关键词
endocrine diseases; lipids; acromegaly; thyroid; cushing; hypogonadism; POLYCYSTIC-OVARY-SYNDROME; LOW-DENSITY-LIPOPROTEIN; CARDIOVASCULAR RISK-FACTORS; GROWTH-HORMONE DEFICIENCY; GH-REPLACEMENT THERAPY; CORONARY-HEART-DISEASE; ESTROGEN PLUS PROGESTIN; BODY-COMPOSITION; INSULIN SENSITIVITY; HEPATIC LIPASE;
D O I
10.1016/j.beem.2022.101667
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Endocrine diseases may be associated with dyslipidaemia and may increase atherosclerotic cardiovascular disease (ASCVD) risk. This chapter describes changes in lipids and lipoproteins in diseases of the pituitary, thyroid, adrenal glands, ovaries, and testes, the mechanisms for these changes, ASCVD risk in these endocrine disorders, and whether treatment of the endocrine disorder im-proves the lipid profile and reduces ASCVD risk. Acromegaly, GH deficiency, Cushing syndrome, chronic glucocorticoid replacement, hypothyroidism, PCOS and male hypogonadism can increase LDL-C and/or TG. Marked reductions in LDL-C are associated with hy-perthyroidism, and extremely low HDL-C levels with testosterone and/or other anabolic steroid abuse. Acromegaly, GH deficiency, Cushing syndrome, and chronic glucocorticoid replacement are associated with increased ASCVD risk. Treatment of acromegaly, GH deficiency, hypothyroidism, Cushing syndrome, and testos-terone deficiency reduce LDL-C, although statin therapy may still be needed. Effects on ASCVD are not known. (c) 2022 Elsevier Ltd. All rights reserved.
引用
收藏
页数:15
相关论文
共 133 条
[1]   Low serum testosterone in men is inversely associated with non-fasting serum triglycerides:: The Tromso study [J].
Agledahl, Ingvild ;
Skjaerpe, Paal-Ande ;
Hansen, John-Bjarne ;
Svartberg, Johan .
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2008, 18 (04) :256-262
[2]   Effects of age at menopause on serum cholesterol, body mass index, and blood pressure [J].
Akahoshi, M ;
Soda, M ;
Nakashima, E ;
Tsuruta, M ;
Ichimaru, S ;
Seto, S ;
Yano, K .
ATHEROSCLEROSIS, 2001, 156 (01) :157-163
[3]   Estrogen-associated severe hypertriglyceridemia with pancreatitis [J].
Aljenedil, Sumayah ;
Hegele, Robert A. ;
Genest, Jacques ;
Awan, Zuhier .
JOURNAL OF CLINICAL LIPIDOLOGY, 2017, 11 (01) :297-300
[4]   Diagnosis and Management of Anabolic Androgenic Steroid Use [J].
Anawalt, Bradley D. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (07) :2490-2500
[5]   Pathophysiology of Dyslipidemia in Cushing's Syndrome [J].
Arnaldi, Giorgio ;
Scandali, Valerio Mattia ;
Trementino, Laura ;
Cardinaletti, Marina ;
Appolloni, Gloria ;
Boscaro, Marco .
NEUROENDOCRINOLOGY, 2010, 92 :86-90
[6]   LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy [J].
Arosio, M ;
Sartore, G ;
Rossi, CM ;
Casati, G ;
Faglia, G ;
Manzato, E .
ATHEROSCLEROSIS, 2000, 151 (02) :551-557
[7]   Polycystic ovary syndrome: insight into pathogenesis and a common association with insulin resistance [J].
Barber, Thomas M. ;
Dimitriadis, George K. ;
Andreou, Avgi ;
Franks, Stephen .
CLINICAL MEDICINE, 2016, 16 (03) :262-266
[8]   Low plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men:: role in altered high density lipoproteins [J].
Beentjes, JAM ;
van Tol, A ;
Sluiter, WJ ;
Dullaart, RPF .
ATHEROSCLEROSIS, 2000, 153 (02) :491-498
[9]  
BENGTSSON BA, 1988, ACTA MED SCAND, V223, P327
[10]   Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome [J].
Berneis, Kaspar ;
Rizzo, Manfredi ;
Lazzaroni, Veronica ;
Fruzzetti, Franca ;
Carmina, Enrico .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (01) :186-189